JP2007508011A - ヒトヒンジコアミメティボディ、組成物、方法および用途 - Google Patents

ヒトヒンジコアミメティボディ、組成物、方法および用途 Download PDF

Info

Publication number
JP2007508011A
JP2007508011A JP2006534031A JP2006534031A JP2007508011A JP 2007508011 A JP2007508011 A JP 2007508011A JP 2006534031 A JP2006534031 A JP 2006534031A JP 2006534031 A JP2006534031 A JP 2006534031A JP 2007508011 A JP2007508011 A JP 2007508011A
Authority
JP
Japan
Prior art keywords
hinge core
core mimetibody
hydrochloride
hinge
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508011A5 (https=
Inventor
ヒーブナー,ジヨージ・エイ
ナイト,デイビツド・エム
スカロン,バーナード・ジエイ
グレイブ,ジヨン
ネスパー,トーマス・シー
フアング,シシ
Original Assignee
セントカー・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントカー・インコーポレーテツド filed Critical セントカー・インコーポレーテツド
Publication of JP2007508011A publication Critical patent/JP2007508011A/ja
Publication of JP2007508011A5 publication Critical patent/JP2007508011A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ceramic Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2006534031A 2003-09-30 2004-09-29 ヒトヒンジコアミメティボディ、組成物、方法および用途 Pending JP2007508011A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30
PCT/US2004/031855 WO2005044807A2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Publications (2)

Publication Number Publication Date
JP2007508011A true JP2007508011A (ja) 2007-04-05
JP2007508011A5 JP2007508011A5 (https=) 2007-11-22

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534031A Pending JP2007508011A (ja) 2003-09-30 2004-09-29 ヒトヒンジコアミメティボディ、組成物、方法および用途

Country Status (21)

Country Link
US (10) US7432378B2 (https=)
EP (1) EP1673348B1 (https=)
JP (1) JP2007508011A (https=)
KR (1) KR20060097024A (https=)
CN (1) CN1886380B (https=)
AR (1) AR045955A1 (https=)
AT (1) ATE427303T1 (https=)
AU (1) AU2004286933B2 (https=)
BR (1) BRPI0414918A (https=)
CA (1) CA2540704A1 (https=)
DE (1) DE602004020364D1 (https=)
ES (1) ES2323178T3 (https=)
HR (1) HRP20060126A2 (https=)
IL (1) IL174677A0 (https=)
NO (1) NO20061950L (https=)
NZ (1) NZ546259A (https=)
PT (1) PT1673348E (https=)
RU (1) RU2006110561A (https=)
TW (1) TW200526637A (https=)
WO (1) WO2005044807A2 (https=)
ZA (1) ZA200603411B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501030A (ja) * 2009-08-05 2013-01-10 スパイダーバイオテック・エッセ・エッレ・エッレ 新規抗病原性ペプチド

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006110561A (ru) * 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола
AU2005226729B2 (en) 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
MX2007014881A (es) * 2005-05-26 2008-02-15 Tibotec Pharm Ltd Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo.
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
JP5301999B2 (ja) * 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Cetp阻害薬
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007069565A1 (ja) * 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
PL2007752T3 (pl) * 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
DE602007008859D1 (de) * 2006-03-31 2010-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
MX2010013727A (es) * 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Uso de un antagonista h4 de histamina para el tratamiento de adherencias postoperatorias.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US20100029942A1 (en) 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
EP2447263A1 (en) 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (en) * 2012-06-05 2013-12-11 Bioprojet Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
EP3798212A4 (en) * 2018-05-22 2022-03-23 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, INSECTICIDE AND ACARICIDE FOR AGRICULTURE AND HORTICULTURE WITH THIS COMPOUND AND METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO1998006703A1 (en) * 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
IL142917A0 (en) * 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
EP1373204B1 (en) * 2001-03-09 2016-10-26 Janssen Pharmaceuticals, Inc. Heterocyclic compounds
RU2006110561A (ru) * 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009030884, Protein expression and purification. 1998, Vol.14, No.1, p.120−124 *
JPN6009030885, Journal of neuroscience research. 2002 Jun 15, Vol.68, No.6, p.655−667 *
JPN6009030886, Cellular and molecular life sciences. 1998, Vol.54, No.5, p.394−404 *
JPN6009030887, Nephrology, dialysis, transplantation. 1999, Vol.14, Suppl.2, p.80−84 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501030A (ja) * 2009-08-05 2013-01-10 スパイダーバイオテック・エッセ・エッレ・エッレ 新規抗病原性ペプチド

Also Published As

Publication number Publication date
RU2006110561A (ru) 2007-10-10
US20090270366A1 (en) 2009-10-29
DE602004020364D1 (de) 2009-05-14
EP1673348A2 (en) 2006-06-28
AU2004286933A1 (en) 2005-05-19
US20050070550A1 (en) 2005-03-31
CA2540704A1 (en) 2005-05-19
KR20060097024A (ko) 2006-09-13
TW200526637A (en) 2005-08-16
NZ546259A (en) 2009-05-31
AU2004286933B2 (en) 2010-11-18
US7723527B2 (en) 2010-05-25
ES2323178T3 (es) 2009-07-08
AR045955A1 (es) 2005-11-16
ATE427303T1 (de) 2009-04-15
US7432378B2 (en) 2008-10-07
US20090270611A1 (en) 2009-10-29
WO2005044807A2 (en) 2005-05-19
US20090247508A1 (en) 2009-10-01
US7662966B2 (en) 2010-02-16
BRPI0414918A (pt) 2006-11-07
CN1886380B (zh) 2010-12-22
WO2005044807A3 (en) 2005-08-11
US20090270613A1 (en) 2009-10-29
US7723359B2 (en) 2010-05-25
CN1886380A (zh) 2006-12-27
US7723526B2 (en) 2010-05-25
US20090264645A1 (en) 2009-10-22
US20090281307A1 (en) 2009-11-12
US20090264646A1 (en) 2009-10-22
PT1673348E (pt) 2009-05-11
NO20061950L (no) 2006-06-29
US20090275748A1 (en) 2009-11-05
US7705143B2 (en) 2010-04-27
EP1673348B1 (en) 2009-04-01
HRP20060126A2 (en) 2008-05-31
IL174677A0 (en) 2006-08-20
ZA200603411B (en) 2007-07-25
US20090264647A1 (en) 2009-10-22
US7705149B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
JP4810428B2 (ja) ヒトepo模倣ヒンジコアミメティボディ、組成物、方法および使用
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
US7718176B2 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
JP2007508011A (ja) ヒトヒンジコアミメティボディ、組成物、方法および用途
AU2003280130B2 (en) Mammalian CH1 deleted mimetibodies, compositions, methods and uses
WO2005081687A2 (en) Human hinge core mimetibodies, compositions, methods and uses
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
JP2006516084A (ja) Cngh0004ポリペプチド、抗体、組成物、方法および使用
HK1138291A (en) Human epo mimentic hinge core mimetibodies, compositions, methods and uses
AU2011202563A1 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
MXPA06003677A (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071001

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329